Search

Your search keyword '"MESH : Twist Transcription Factor"' showing total 2 results
Start Over Descriptor "MESH : Twist Transcription Factor" Topic business
2 results on '"MESH : Twist Transcription Factor"'

1. Revisiting the canonical tumour progression model

Author

Anne-Pierre Morel, George W. Hinkal, Stéphane Ansieau, Alain Puisieux, equipe 2, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncogénèse et progression tumorale, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Claude Bernard Lyon 1 (UCBL), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon ( CRCL ), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Pathology, MESH: Oncogenes, MESH : Models, Biological, MESH : Tumor Escape, Metastasis, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Twist transcription factor, 0302 clinical medicine, Cell Movement, Neoplasms, MESH : Cell Movement, MESH: Neoplasms, Twist, MESH: Models, Theoretical, MESH: Cell Movement, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, MESH: Twist Transcription Factor, General Medicine, MESH : Epithelial-Mesenchymal Transition, Cell Transformation, Neoplastic, 030220 oncology & carcinogenesis, Disease Progression, MESH: Tumor Escape, MESH: Disease Progression, medicine.medical_specialty, Epithelial-Mesenchymal Transition, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Models, Biological, 03 medical and health sciences, Text mining, medicine, Humans, Epithelial–mesenchymal transition, 030304 developmental biology, MESH : Oncogenes, MESH: Humans, business.industry, MESH : Models, Theoretical, Disease progression, Twist-Related Protein 1, MESH : Twist Transcription Factor, MESH : Humans, MESH: Models, Biological, MESH : Cell Transformation, Neoplastic, Cell movement, Oncogenes, MESH : Disease Progression, Models, Theoretical, medicine.disease, MESH : Neoplasms, MESH: Epithelial-Mesenchymal Transition, Tumor Escape, MESH: Cell Transformation, Neoplastic, Cancer research, business
Abstract

International audience

Published
2011
Full Text
View/download PDF

2. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status

Author

Jean P. Thiery, Hugues Bittard, Marie E. Fondrevelle, Franck Monnien, Hervé Wallerand, Robert E. Reiter, Dominique Chopin, Bernadette Kantelip, Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques

Subjects
Oncology, Male, Pathology, MESH : Immunohistochemistry, MESH : Aged, Kaplan-Meier Estimate, MESH: Cadherins, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Risk Factors, Risk Factors, MESH : Neoplasm Staging, MESH : Female, MESH: Kaplan-Meiers Estimate, Stage (cooking), MESH: Aged, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, MESH : Prognosis, Smoking, MESH: Twist Transcription Factor, Nuclear Proteins, Anatomical pathology, MESH: Neoplasm Staging, Middle Aged, Cadherins, Prognosis, Immunohistochemistry, MESH : Risk Factors, 3. Good health, MESH: Urinary Bladder Neoplasms, MESH : Smoking, MESH : Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Disease Progression, MESH: Disease Progression, Female, MESH : Cadherins, medicine.medical_specialty, MESH: Smoking, Urology, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Multivariate Analysis, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH : Middle Aged, Epithelial–mesenchymal transition, Risk factor, MESH : Aged, 80 and over, 030304 developmental biology, Aged, Neoplasm Staging, Proportional Hazards Models, Bladder cancer, MESH: Humans, Proportional hazards model, business.industry, Twist-Related Protein 1, MESH : Twist Transcription Factor, MESH : Humans, Cancer, MESH : Multivariate Analysis, MESH : Nuclear Proteins, MESH: Immunohistochemistry, MESH : Kaplan-Meiers Estimate, MESH : Disease Progression, medicine.disease, MESH : Proportional Hazards Models, MESH: Male, Urinary Bladder Neoplasms, Multivariate Analysis, business, MESH: Nuclear Proteins, MESH: Female
Abstract

International audience; OBJECTIVES: Twist is considered as transcription factor that regulates epithelial mesenchymal transition (EMT) by at least inhibition of E-cadherin expression. EMT is a key event in the tumor invasion process. The purpose of this study is to investigate the expression of Twist but also those of E- and N-cadherin in human primary bladder tumor and to evaluate its prognostic value. As smoking cigarettes is a strong bladder cancer risk factor, we tried to evaluate the impact of the tobacco status on these molecular abnormalities. MATERIALS AND METHODS: To delineate on the oncogenic role for Twist in human bladder cancer, we evaluated the E- and N-cadherin but also Twist expression (n = 70) by immunohistochemistry. We evaluated the prognostic value of these expressions. Moreover, we tried to correlate these protein expressions to the smoking status of the patients. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. RESULTS: Of the 70 bladder tumors, 28 (40%) cases were positive for Twist expression, 16 (23%) cases were negative for E-cadherin expression, and 12 (17%) were positive for N-cadherin expression. When categorized into negative vs. positive expression, Twist was associated with the stage (P = 0.001), the grade (P < 0.001), the progression (P = 0.02), and the E-cadherin expression (P = 0.01). Moreover, positive Twist expression clearly predicted poorer PFS (P = 0.02). In the multivariate analysis, both positive Twist expression and loss of E-cadherin expression were independent prognostic factors for PFS (P = 0.046 and P = 0.001, respectively) and only loss of E-cadherin expression for the OS (P < 0.001). We also demonstrated that almost 60% (16/28) of patients with Twist-positive expression were current smokers at the time of the diagnosis, corroborating the fact that smoking modulates the expression of EMT markers including Twist. CONCLUSION: Positive Twist expression may be a useful prognostic marker for patients with bladder cancer. Its expression seems to be correlated to the tobacco status of the patients.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results